Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
The planned initial study will generate safety and drug-processing data to guide the subsequent multiple ascending dose study.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Marvel Biosciences (MBCOF) has signed a letter of intent with Novatech for the planned first-in-human Phase 1 trial of MB-204. The single ascending dose study, which tests increasing doses, is expected to begin in Q4 2026 in Australia. It will assess safety, tolerability and pharmacokinetics—how the body processes the drug—and include a potential biomarker and several cognitive endpoints. Its data will inform the subsequent multiple ascending dose study.
Marvel reports effects across Oprm1, Rett and Fragile X mouse models, including effects after treatment stopped. The company has recently closed a private placement and cites a 43% tax credit in Australia. Separately, Marvel plans an experiment with the iBrain Inserm Lab comparing MB-204 with Yamo Pharmaceuticals’ L1-79 in an autism mouse model. Marvel is also preparing manuscripts for scientific publication.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.MB-204’s single ascending dose study is expected to begin in Q4 2026 in Australia.
- Moderate pointPrivate placement recently closed ahead of the planned Phase 1 program.
- Minor point. Forward-looking: it has not happened yet and may not happen.Initial human study will assess safety, tolerability, drug processing, a potential biomarker and several cognitive endpoints.
- Minor point. Forward-looking: it has not happened yet and may not happen.Single ascending dose data will inform the subsequent multiple ascending dose study’s design.
- Minor pointMarvel reports preclinical effects across Oprm1, Rett and Fragile X models, including effects after treatment stopped.
4 minor points
- Minor pointAustralia offers a 43% tax credit, Marvel says.
- Minor pointLiquid MB-204 formulation improved drug processing in preclinical studies; development received a National Research Council of Canada grant.
- Minor point. Forward-looking: it has not happened yet and may not happen.iBrain Inserm Lab collaboration plans to compare MB-204 with L1-79 in an autism mouse model.
- Minor pointScientific manuscripts are being prepared for publication.
Negative
- Moderate pointNovatech trial arrangement remains at the letter-of-intent stage, rather than a definitive agreement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for small to mid-sized biotech and pharmaceutical companies.
The signing of the LOI marks an important development milestone for Marvel as MB-204 advances from preclinical development toward first-in-human clinical evaluation. The planned Phase 1 program is designed to establish the initial safety, tolerability and pharmacokinetic profile of MB-204 in humans, while generating clinical data to inform subsequent development. This transition is supported by encouraging preclinical findings, with MB-204 demonstrating immediate, robust and durable effects, including measurable carry-over effects following cessation of treatment, across multiple mouse models relevant to neurodevelopmental disorders, including Oprm1, Rett and Fragile X models. Together, these findings provide a scientific rationale for advancing MB-204 into clinical development and establishing its initial human safety and pharmacokinetic profile.
“We are pleased to begin moving forward into a Phase I trial for MB-204 in partnership with Novatech following the recent closing of our private placement and signing of a letter-of-intent,” said Marvel’s CEO Rod Matheson. “Novatech provides end-to-end clinical trial management, site selection, regulatory and ethics submissions, biostatistics, data management, and medical writing. They have an early-phase clinical focus including First-in-Human and proof-of-concept studies. The trial will be conducted in Australia which offers a streamlined and favourable regulatory environment as well as a generous
Corporate Update:
- The Phase I single ascending dose (SAD) study is expected to begin in Q4 of 2026. The SAD study is designed to test the safety, tolerability and pharmacokinetics (PK) of MB-204 as well as include a potential biomarker and several cognitive endpoints. The data from the SAD will inform the design of the subsequent multiple ascending dose (MAD) study.
- Marvel has previously developed a novel liquid-based formulation of MB-204 for its Phase 1 trial SAD study which improved the drug’s PK in pre-clinical studies and may facilitate administration in patient populations where swallowing solid dosage forms may present challenges. The work was conducted with a grant from the National Research Council of Canada.
- The Company is currently preparing manuscripts for scientific publication and will provide a future update on conference participation.
- In collaboration with the iBrain Inserm Lab, Marvel is planning an upcoming experiment to test the efficacy of MB-204 against Yamo Pharmaceuticals’ L1-79 (repurposed racemic N-methyl Tyrosine) in a mouse model of autism. L1-79 recently demonstrated efficacy in a Phase 2 study.
About Marvel Biosciences Corp.
Marvel Biosciences Corp. (TSXV:MRVL | OTCQB:MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pharmaceutical development biotechnology company entering Phase 1 clinical stage. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson’s drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer’s Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information: Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer
Email: rod@marvelbiosciences.com
Dr. Mark Williams, President and Chief Science Officer
Email: mark@marvelbiosciences.com
Tel: 403 770 2469Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Marvel Biosciences’ MB-204 Phase 1 trial expected to begin?
The MB-204 single ascending dose study is expected to begin in Q4 2026 in Australia. Marvel has signed a letter of intent with Novatech for the planned Phase 1 program.
What will Marvel Biosciences’ initial MB-204 human study measure?
The study will assess safety, tolerability and pharmacokinetics, meaning how the body processes MB-204. It will also include a potential biomarker and several cognitive endpoints. The results will inform the design of the subsequent multiple ascending dose study.
Why did Marvel Biosciences develop a liquid formulation of MB-204?
The liquid formulation improved MB-204’s pharmacokinetics in preclinical studies and, Marvel says, may help patients who have difficulty swallowing solid dosage forms. It was developed for the Phase 1 single ascending dose study with a grant from the National Research Council of Canada.